NITI Aayog just put a price tag on India's biotech dream.
₹50,000 crore.
The goal? Turn India into a nearly $700 billion bio-economy by 2035.
Released on Thursday, this roadmap isn't just another government wishlist.
It's targeting the one problem that's quietly killed hundreds of Indian breakthroughs.
Here's the brutal truth about Indian biotech.
Labs discover something brilliant.
Investors won't touch it — too risky, too early.
Factories won't scale it — no proven demand yet.
So the research just… dies.
Scientists have a name for this gap: the valley of death.
This new fund is built to bridge exactly that.
Six mission-mode programmes sit at the core:
Alongside faster regulatory approvals, AI-led biotechnology, and tighter academia-industry ties.
The pitch is simple: stop losing Indian science to slow paperwork and thin capital.
India's bio-economy went from $10 billion in 2014 to $165.7 billion in 2024.
Sixteen-fold growth in a decade.
Now the target jumps again — to nearly $700 billion by 2035.
And the roadmap doesn't stop there.
By 2047, the ambition is $2.6 trillion, roughly 8-10% of India's entire GDP.
This isn't just about pharma or agriculture.
It's about who controls the next global supply chain — genes, vaccines, biofuels, food security.
The roadmap even eyes a spot among the world's top three biotech powers.
👉 The money is on the table.
👉 The missions are mapped.
Now it comes down to execution.
That's all for now!
